Streetbeat News

Revenues

DOMO

Domo provided Q2 and FY24 guidance, with Q2 revenue expected between $78.5M-$79.5M and FY24 revenue between $323M-$330M. Q2 EPS is estimated at $(0.07)-$(0.11) and FY24 EPS at $(0.27)-$(0.39).

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 8:16 pm

MRVL

Marvell Technology forecasts its AI revenue in fiscal 2024 to at least double from the prior year and continue to grow rapidly in the coming years.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:14 pm

ME

23andMe Holdings forecasts FY24 revenue to be between $340M and $365M, surpassing the estimated $298.41M.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:14 pm

WDAY

Workday forecasts FY24 subscription revenue to be between $6.55B and $6.575B, and Q2 subscription revenue to be between $1.611B and $1.613B.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:10 pm

ULTA

Ulta Beauty has raised its fiscal 2023 revenue outlook from $10.95B-$11.05B to $11B-$11.1B, slightly below the $11.12B estimate. Other financial metrics, such as comparable sales, new stores, and share repurchases, remain unchanged.

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 8:09 pm

RH

RH has raised its FY23 revenue guidance to $3B-$3.1B.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:07 pm

ADSK

Autodesk expects Q2 2024 revenue to be between $1.315B and $1.325B, slightly below the estimated $1.33B.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 8:03 pm

AMC

MoviePass has relaunched nationwide with a new pricing model, offering access to over 4,000 movie theaters, including AMC Theaters, Regal Cinemas, and Cinemark. The new subscription plans range from $10 to $40 per month, with varying limits on the number of movies.

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 5:25 pm

TITN

Titan Machinery shares are trading lower after reporting worse-than-expected revenue results. The company also reiterated its FY24 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 4:57 pm

COSM

Cosmos Health (NASDAQ:COSM) has entered into a binding Letter of Intent to acquire German pharmaceutical distributor Docpharm GmbH. The acquisition is expected to boost Cosmos Health's annual revenue by approximately 70% by the end of 2025 compared to FY 2022.

Portfolio Pulse from Happy Mohamed

May 25, 2023 | 3:25 pm